Poststroke Fatigue - Developing and Testing a Program to Reduce and Cope With Fatigue
Fatigue is a common complaint after stroke, reported by 39-72% of patients. Poststroke fatigue is related to poor neurological recovery, low level of activities of daily living, decreased quality of life and may possibly affect the ability to return to work. Little is known about strategies addressing post-stroke fatigue and their effectiveness.
Aim: to develop, test and evaluate a health promotion program based on strategies addressing poststroke fatigue.
調査の概要
詳細な説明
Fatigue is a common complaint after stroke, reported by 39-72% of patients. It has been shown that poststroke fatigue may be related to poor neurological recovery, low level of activities of daily living and decreased quality of life. However, little is known about strategies to address poststroke fatigue and the effectiveness of such strategies.
Objective The aim of the study is to develop a program based on strategies to address poststroke fatigue and to test and evaluate the program.
Material and Methods Intervention Mapping is the overall approach of the study. It describes a protocol for the development of theory- and evidence-based health promotion programmes.
Step 1) The program is developed based on a needs assessment. Existing knowledge about physical, psychosocial and environmental factors associated with poststroke fatigue is mapped in a literature review.
Step 2) The program will be tested in a pilot study (controlled trial). In addition to conventional treatment, the patients in the intervention group will participate in the program for a period of 12 weeks. The control group will receive conventional treatment only.
Step 3) Evaluation of the program: Primary outcome measure will be fatigue, measured on the Multidimensional Fatigue Inventory-20. Secondary outcome measures will be identified during the development of the program. Patients will be tested at baseline, after 3 months and after 6 months. The effect size in the pilot study will be assessed and will be used in order to estimate the required sample size for a large-scale randomized controlled trial on formally testing the efficacy of the program.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Central Denmark Region
-
Aarhus、Central Denmark Region、デンマーク、8000
- Department of Neurology, Aarhus University Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients with first ever stroke
- > 18 year
- Living in the area of Aarhus(intervention group) and patients living in the area of Holstebro (control group).
- Multidimensional Fatigue Inventory-20/Generel Fatigue > 12.
- The patient must be able to give informed consent
- Walking without person support.
- Walking aids is accepted.
Exclusion Criteria:
- Neurological problems related to acute stroke(severe aphasia, decreased level of conscience or decreased attention)
- Other neurologic or psychiatric deseases (including dementia, non treated depression, misuse of alcohol eller medicin)
- Severe co-morbidity (including cancer, blindness or deathness)
- Not-danish speaking.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：防止
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Lifestyle counseling
Testing of the teory- and evidence based health promotion program.
Patients will participate in a 13 weeks program.
|
A 13 weeks organized program:
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Multidimensional Fatigue Inventory 20
時間枠：Change from baseline in MFI-20 at 3 and 6 months
|
The multidimensional Fatigue Inventory 20 is a multidimensional fatigue score covering five dimensions of fatigue: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Activity.
Pathologic Fatigue is defined as a score ≥ 12 on the General Fatigue dimension.
|
Change from baseline in MFI-20 at 3 and 6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The general self-efficacy scale
時間枠：Change from baseline in the generel self-efficacy scale at 3 and 6 months
|
The general self-efficacy scale is a scale measuring how individuals cope with distressing situations
|
Change from baseline in the generel self-efficacy scale at 3 and 6 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Marit Kirkevold, Professor、University of Aarhus, Health, Nursing Science
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。